Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6409MR)

This product GTTS-WQ6409MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6409MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1199MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ3157MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AR-101
GTTS-WQ12283MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ12641MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ11940MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ7545MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ7809MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ4250MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW